PUBLIC COMPANY
saveInversago Pharma Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
- phase2Study of INV-202 in Patients With Obesity and Metabolic Syndrome
- phase1Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
- phase1A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
🐶 Hiring Signal
News
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisNovo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…fiercebiotech · 16d ago
- Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, SanofiCorbus Pharmaceuticals’ phase 1b obesity trial has generated evidence that its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The…fiercebiotech · 17d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 1mo ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that